AI Engines For more Details: Perplexity Kagi Labs You
Antioxidant Activity: Glutathione is a potent antioxidant that helps to neutralize harmful free radicals in the body. Free radicals are unstable molecules that can damage cells and contribute to aging and various diseases. Glutathione acts as a first line of defense against oxidative stress, helping to protect cells from damage and maintain cellular integrity.
Detoxification: Glutathione plays a crucial role in the detoxification process by binding to and neutralizing toxins, heavy metals, and other harmful substances in the body. It helps to facilitate the removal of these toxins from cells and tissues, promoting overall detoxification and reducing the risk of toxicity-related diseases.
Immune Function: Glutathione supports immune function by enhancing the activity of immune cells, such as T cells and natural killer cells. It helps to regulate the immune response, modulate inflammation, and protect immune cells from oxidative damage. Adequate glutathione levels are essential for maintaining a healthy immune system and protecting against infections and diseases.
Cellular Repair and Regeneration: Glutathione is involved in various cellular processes, including DNA synthesis, repair, and regeneration. It helps to maintain the integrity of cell membranes, proteins, and other cellular structures, promoting overall cell health and longevity. Glutathione also plays a role in cell signaling pathways that regulate cell growth, proliferation, and apoptosis (programmed cell death).
Neurological Health: Glutathione has been studied for its potential neuroprotective effects in the brain. It helps to protect neurons from oxidative damage, reduce inflammation, and improve mitochondrial function. Glutathione levels are particularly high in the brain, where it plays a crucial role in maintaining neuronal health and function. Dysregulation of glutathione metabolism has been implicated in neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis.
Respiratory Health: Glutathione has been investigated for its potential therapeutic role in respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. It helps to reduce inflammation in the airways, improve lung function, and protect against oxidative damage caused by environmental pollutants and cigarette smoke.
Rank | Probiotic | Impact |
---|---|---|
species | Bacteroides uniformis | Increases |
species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
---|---|---|---|---|
0 | 2 | Enterobacteriaceae | family | Decreases |
0 | 1 | Bacteroidaceae | family | Increases |
0 | 1 | Selenomonadaceae | family | Increases |
0 | 1 | Veillonellaceae | family | Increases |
1 | 0 | Escherichia | genus | Decreases |
1 | 0 | Plesiomonas | genus | Decreases |
1 | 0 | Shigella | genus | Decreases |
1 | 0 | Bacteroides | genus | Increases |
1 | 0 | Megamonas | genus | Increases |
1 | 0 | Megasphaera | genus | Increases |
0 | 1 | environmental samples | no rank | Decreases |
0 | 1 | environmental samples | no rank | Decreases |
0 | 1 | unclassified Escherichia | no rank | Decreases |
0 | 1 | unclassified Shigella | no rank | Decreases |
0 | 1 | environmental samples | no rank | Increases |
0 | 1 | environmental samples | no rank | Increases |
0 | 1 | environmental samples | no rank | Increases |
0 | 1 | unclassified Bacteroides | no rank | Increases |
0 | 1 | unclassified Megamonas | no rank | Increases |
0 | 1 | unclassified Megasphaera | no rank | Increases |
0 | 1 | Plesiomonas shigelloides | species | Decreases |
0 | 1 | Escherichia coli | species | Decreases |
0 | 1 | Shigella flexneri | species | Decreases |
0 | 1 | Shigella dysenteriae | species | Decreases |
0 | 1 | Shigella boydii | species | Decreases |
0 | 1 | Escherichia albertii | species | Decreases |
0 | 1 | Shigella sonnei | species | Decreases |
0 | 1 | Escherichia fergusonii | species | Decreases |
0 | 1 | Escherichia marmotae | species | Decreases |
0 | 1 | Escherichia ruysiae | species | Decreases |
0 | 1 | Bacteroides zoogleoformans | species | Increases |
0 | 1 | Bacteroides coprosuis | species | Increases |
0 | 1 | Bacteroides heparinolyticus | species | Increases |
0 | 1 | Bacteroides zhangwenhongii | species | Increases |
0 | 1 | Bacteroides nordii | species | Increases |
0 | 1 | Bacteroides stercoris | species | Increases |
0 | 1 | Bacteroides cellulosilyticus | species | Increases |
0 | 1 | Bacteroides intestinalis | species | Increases |
0 | 1 | Bacteroides caccae | species | Increases |
0 | 1 | Bacteroides eggerthii | species | Increases |
0 | 1 | Bacteroides helcogenes | species | Increases |
0 | 1 | Bacteroides faecis | species | Increases |
0 | 1 | Bacteroides salyersiae | species | Increases |
0 | 1 | Bacteroides faecium | species | Increases |
0 | 1 | Bacteroides humanifaecis | species | Increases |
0 | 1 | Megasphaera massiliensis | species | Increases |
0 | 1 | Bacteroides caecimuris | species | Increases |
0 | 1 | Bacteroides thetaiotaomicron | species | Increases |
0 | 1 | Bacteroides xylanisolvens | species | Increases |
0 | 1 | Bacteroides fragilis | species | Increases |
0 | 1 | Bacteroides luhongzhouii | species | Increases |
0 | 1 | Bacteroides uniformis | species | Increases |
0 | 1 | Bacteroides ovatus | species | Increases |
0 | 1 | Megasphaera stantonii | species | Increases |
0 | 1 | Bacteroides acidifaciens | species | Increases |
0 | 1 | Bacteroides caecigallinarum | species | Increases |
0 | 1 | Bacteroides caecimuri | species | Increases |
0 | 1 | Bacteroides chinchillae | species | Increases |
0 | 1 | Bacteroides clarus | species | Increases |
0 | 1 | Bacteroides congonensis | species | Increases |
0 | 1 | Bacteroides cutis | species | Increases |
0 | 1 | Bacteroides denticanum | species | Increases |
0 | 1 | Bacteroides difficilis | species | Increases |
0 | 1 | Bacteroides faecalis | species | Increases |
0 | 1 | Bacteroides faecichinchillae | species | Increases |
0 | 1 | Bacteroides finegoldii | species | Increases |
0 | 1 | Bacteroides fluxus | species | Increases |
0 | 1 | Bacteroides galacturonicus | species | Increases |
0 | 1 | Bacteroides gallinaceum | species | Increases |
0 | 1 | Bacteroides gallinarum | species | Increases |
0 | 1 | Bacteroides graminisolvens | species | Increases |
0 | 1 | Bacteroides ihuae | species | Increases |
0 | 1 | Bacteroides ilei | species | Increases |
0 | 1 | Bacteroides koreensis | species | Increases |
0 | 1 | Bacteroides kribbi | species | Increases |
0 | 1 | Bacteroides luti | species | Increases |
0 | 1 | Bacteroides mediterraneensis | species | Increases |
0 | 1 | Bacteroides muris (ex Fokt et al. 2023) | species | Increases |
0 | 1 | Bacteroides ndongoniae | species | Increases |
0 | 1 | Bacteroides oleiciplenus | species | Increases |
0 | 1 | Bacteroides parvus | species | Increases |
0 | 1 | Bacteroides propionicifaciens | species | Increases |
0 | 1 | Bacteroides propionicigenes | species | Increases |
0 | 1 | Bacteroides pyogenes | species | Increases |
0 | 1 | Bacteroides reticulotermitis | species | Increases |
0 | 1 | Bacteroides rhinocerotis | species | Increases |
0 | 1 | Bacteroides rodentium | species | Increases |
0 | 1 | Bacteroides sp | species | Increases |
0 | 1 | Bacteroides sp. C13EG172 | species | Increases |
0 | 1 | Bacteroides stercorirosoris | species | Increases |
0 | 1 | Bacteroides timonensis | species | Increases |
0 | 1 | Candidatus Bacteroides intestinigallinarum | species | Increases |
0 | 1 | Megamonas rupellensis | species | Increases |
0 | 1 | Megasphaera butyrica | species | Increases |
0 | 1 | Megasphaera cerevisiae | species | Increases |
0 | 1 | Megasphaera genomosp. C1 | species | Increases |
0 | 1 | Megasphaera genomosp. type_1 | species | Increases |
0 | 1 | Megasphaera hominis | species | Increases |
0 | 1 | Megasphaera indica | species | Increases |
0 | 1 | Megasphaera lornae | species | Increases |
0 | 1 | Megasphaera micronuciformis | species | Increases |
0 | 1 | Megasphaera paucivorans | species | Increases |
0 | 1 | Megasphaera sueciensis | species | Increases |
0 | 1 | Megasphaera vaginalis (ex Bordigoni et al. 2020) | species | Increases |
0 | 1 | Megasphaera vaginalis (ex Srinivasan et al. 2021) | species | Increases |
0 | 1 | Megamonas hypermegale | species | Increases |
0 | 1 | Megasphaera hexanoica | species | Increases |
0 | 1 | Megasphaera elsdenii | species | Increases |
0 | 1 | Megamonas funiformis | species | Increases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.2 | -0.2 | |
Acne | 0.9 | -0.9 | |
ADHD | 0.6 | 1.6 | -1.67 |
Allergic Rhinitis (Hay Fever) | 0.5 | 1.2 | -1.4 |
Allergies | 3.1 | 0.5 | 5.2 |
Allergy to milk products | 1.2 | 1.1 | 0.09 |
Alopecia (Hair Loss) | 0.7 | -0.7 | |
Alzheimer's disease | 1.8 | 2.8 | -0.56 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.9 | 0.8 | 1.37 |
Ankylosing spondylitis | 2.5 | 1.5 | 0.67 |
Anorexia Nervosa | 0.8 | 0.8 | |
Antiphospholipid syndrome (APS) | 0.6 | 0.2 | 2 |
Asthma | 1.2 | 2 | -0.67 |
Atherosclerosis | 0.6 | 0.8 | -0.33 |
Atrial fibrillation | 0.9 | 1.8 | -1 |
Autism | 2.7 | 4.2 | -0.56 |
Autoimmune Disease | 1 | 1 | |
Barrett esophagus cancer | 0.9 | 0.9 | |
benign prostatic hyperplasia | 1.6 | 1.6 | |
Biofilm | 0.6 | 0.6 | |
Bipolar Disorder | 1.6 | 0.6 | 1.67 |
Brain Trauma | 0.6 | 0.6 | 0 |
Breast Cancer | 0.6 | 0.6 | |
Cancer (General) | 0.1 | 0.1 | |
Carcinoma | 1.1 | 0.6 | 0.83 |
Celiac Disease | 1.8 | 1.7 | 0.06 |
Cerebral Palsy | 0.6 | 0.6 | 0 |
Chronic Fatigue Syndrome | 1.2 | 1.3 | -0.08 |
Chronic Kidney Disease | 1 | 1.3 | -0.3 |
Chronic Lyme | 0.6 | 0.6 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.6 | 0.6 | 0 |
Chronic Urticaria (Hives) | 1.3 | 1.3 | |
Coagulation / Micro clot triggering bacteria | 1.6 | 1.6 | |
Cognitive Function | 1.5 | -1.5 | |
Colorectal Cancer | 3.3 | 2.9 | 0.14 |
Constipation | 2.5 | 0.9 | 1.78 |
Coronary artery disease | 2.4 | 2.4 | |
COVID-19 | 3.7 | 1.6 | 1.31 |
Crohn's Disease | 4.4 | 2.2 | 1 |
Cushing's Syndrome (hypercortisolism) | 0.6 | 0.6 | |
cystic fibrosis | 1.7 | 1.7 | |
d-lactic acidosis (one form of brain fog) | 0.6 | 0.6 | |
deep vein thrombosis | 2.2 | 0.2 | 10 |
Denture Wearers Oral Shifts | 0.6 | -0.6 | |
Depression | 3.5 | 4 | -0.14 |
Eczema | 2.1 | 0.3 | 6 |
Endometriosis | 1.6 | 1.2 | 0.33 |
Epilepsy | 2.8 | 2.3 | 0.22 |
erectile dysfunction | 1.1 | 1.2 | -0.09 |
Fibromyalgia | 0.8 | 0.8 | |
Functional constipation / chronic idiopathic constipation | 3.9 | 1.9 | 1.05 |
gallstone disease (gsd) | 1.1 | 0.2 | 4.5 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.2 | -0.2 | |
Generalized anxiety disorder | 2.2 | 0.6 | 2.67 |
Gout | 0 | 1.9 | 0 |
Graves' disease | 1.8 | 1.2 | 0.5 |
Gulf War Syndrome | 0.4 | 0.3 | 0.33 |
Halitosis | 1.2 | -1.2 | |
Hashimoto's thyroiditis | 1.2 | 0.8 | 0.5 |
Heart Failure | 1.6 | 1.2 | 0.33 |
Hidradenitis Suppurativa | 0.6 | -0.6 | |
High Histamine/low DAO | 1.2 | 1.2 | |
hypercholesterolemia (High Cholesterol) | 0.6 | 0.6 | 0 |
hyperglycemia | 2.2 | 2.2 | |
hypertension (High Blood Pressure | 2 | 0.6 | 2.33 |
Hypoxia | 1.6 | 0.9 | 0.78 |
IgA nephropathy (IgAN) | 0.9 | 0.6 | 0.5 |
Inflammatory Bowel Disease | 3.2 | 1.8 | 0.78 |
Insomnia | 1.1 | 1.2 | -0.09 |
Intelligence | 0.6 | 0.8 | -0.33 |
Intracranial aneurysms | 1.5 | 0.6 | 1.5 |
Irritable Bowel Syndrome | 2.6 | 1.6 | 0.63 |
ischemic stroke | 1.2 | 3.1 | -1.58 |
Liver Cirrhosis | 2.3 | 2.6 | -0.13 |
Long COVID | 2.4 | 2 | 0.2 |
Lung Cancer | 1 | 0.1 | 9 |
Lymphoma | 1 | 1 | |
Mast Cell Issues / mastitis | 1 | 1 | |
ME/CFS with IBS | 0.6 | 0.6 | |
ME/CFS without IBS | 0.6 | 0.6 | |
Menopause | 0.2 | -0.2 | |
Metabolic Syndrome | 3.2 | 2.4 | 0.33 |
Mood Disorders | 2.9 | 3.7 | -0.28 |
Multiple Sclerosis | 2.4 | 2.4 | |
Multiple system atrophy (MSA) | 1.2 | 1.2 | |
myasthenia gravis | 1 | 0 | 0 |
neuropathic pain | 0.6 | 0.6 | |
Neuropathy (all types) | 1.1 | -1.1 | |
neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.3 | 1 |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.2 | 1.1 | 1 |
NonCeliac Gluten Sensitivity | 0.6 | 0.6 | 0 |
Obesity | 2.7 | 1.5 | 0.8 |
obsessive-compulsive disorder | 1.7 | 1.2 | 0.42 |
Osteoarthritis | 1.1 | 0.8 | 0.38 |
Osteoporosis | 2.2 | 1.2 | 0.83 |
pancreatic cancer | 0 | 0.3 | 0 |
Parkinson's Disease | 2.4 | 2.8 | -0.17 |
Polycystic ovary syndrome | 1.9 | 1.1 | 0.73 |
Postural orthostatic tachycardia syndrome | 0 | 0 | |
Premenstrual dysphoric disorder | 0.6 | 0.6 | |
primary biliary cholangitis | 0.2 | 0.3 | -0.5 |
Primary sclerosing cholangitis | 0.6 | -0.6 | |
Psoriasis | 1.2 | 1.1 | 0.09 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.7 | 2.2 | 0.23 |
Rosacea | 0.6 | 0.3 | 1 |
Schizophrenia | 0.9 | 2 | -1.22 |
scoliosis | 0.6 | 0.6 | |
Sjögren syndrome | 1.8 | 0.6 | 2 |
Sleep Apnea | 1.1 | 0.9 | 0.22 |
Slow gastric motility / Gastroparesis | 0.6 | 0.6 | 0 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.6 | 0 |
Stress / posttraumatic stress disorder | 1.8 | 0.6 | 2 |
Systemic Lupus Erythematosus | 1 | 1.7 | -0.7 |
Tourette syndrome | 0.6 | 0.6 | |
Type 1 Diabetes | 2.2 | 1 | 1.2 |
Type 2 Diabetes | 3.4 | 3 | 0.13 |
Ulcerative colitis | 3.9 | 1.1 | 2.55 |
Unhealthy Ageing | 0 | 1.4 | 0 |
Vitiligo | 1.4 | -1.4 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]